A Phase III trial evaluating AstraZeneca's Tagrisso lung cancer drug has met its primary endpoint in showing superior progression-free survival compared to standard chemotherapy. The AURA3 randomized trial
The company focused on the discovery, development and commercialization of new minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat GI and cardio-renal
MCL is a rare sub-type of non-Hodgkin's lymphoma, which begins in the lymph nodes and moves to other organs, resulting lymphomas tumours. The data supporting approval was generated
The collaboration will assess the use of Avacta’s Affimer technology in combination with Glythera’s PermaLink conjugation chemistry. The companies will develop materials and methods to be leveraged in
Redox has a license to vipadenant, a small molecule adenosine A2a receptor antagonist that may disrupt key immunosuppressive pathways in the tumor microenvironment in various cancers. Juno plans
A new joint venture company, Denceptor Therapeutics, will use Abzena Inside immunotherapeutic products and Baylor Scott & White’s dendritic cell receptor-targeting antibodies to carry out its work. Denceptor has the
The deal resolves the litigation relating to Sandoz’s generic fulvestrant product, for which it is seeking approval from the US Food and Drug Administration (FDA). The US Faslodex
The new collaboration on a phase 1b study will assess the safety and tolerability of Lilly's cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor abemaciclib (LY2835219) in combination
The study met its primary endpoint of a significant reduction in in depression symptoms from baseline compared to placebo as measured by the total score in the Hamilton
Xiidra is the first medication in a new class of drugs, dubbed lymphocyte function-associated antigen 1 (LFA-1) antagonist, approved by the US regulator for dry eye disease. It
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.